Reassuringly, this platform re-identified several urine protein biomarkers that had previously been implicated as biomarkers for LN, including adiponectin, NGAL, and TWEAK; although all of these proteins were elevated in the urine of active LN patients in the aptamer-based screen, they did not rank within the top 50, based on fold-change or p-values. Here, LCN2 is linked to lobular neoplasia.